Abstract:Abstract Background Immunotherapy (IO) is expected to become a part of standard neoadjuvant therapy for early-stage, triple-negative breast cancer. However, only a minority of patients benefit from the addition of IO to standard neoadjuvant chemotherapy (NACT). Biomarkers of IO response in the metastatic setting, such as PD-L1 expression, fail to predict benefit from IO in the early-stage setting. Given the financial cost of IO and the potential for irreversible, immune-related toxicities, predictive biomarkers are desperately needed. SimBioSys TumorScope (TS), a commercially available biophysical model, has been previously validated as a highly accurate predictor of response to standard NAT regimens. TS has the potential to identify patients treated with IO who would have responded well to standard NACT, and those who truly benefited from IO, enabling biomarker discovery. Methods We identified 17 pts who received pembrolizumab in combination with standard NACT. From these cases, dynamic contrast-enhanced MRIs were assessed from multiple timepoints throughout treatment. Using a proprietary convolutional neural net, the tumor region from each MRI was segmented to assess volume over time. We compared actual tumor volumes to predicted response to standard NACT (without pembrolizumab) generated with the TS platform. By contrasting the tumor volume across the simulation and the longitudinal MRI timepoints, a metric of response directly attributable to pembrolizumab (“IO benefit”) was generated. Clinical, radiological, metabolic, tumor morphology, and microvasculature features were extracted from TS simulations, and after quality control and removal of redundant metrics, used in linear models as predictors of IO benefit. Results Nine clinical, seven metabolic, 16 microvasculature, ten tumor morphology, and 77 radiological features were used as individual predictors of IO benefit in linear models. Eight out of 17 cases had positive IO benefit values. In all, 12 out of the 119 metrics of interest nominally significant predictors of IO benefit (p<0.05). Top relationships of interest included: tumor convex hull surface area to volume ratio (b=-51.4, p=0.010), maximum 2D diameter column (a metric of longest tumor dimension) (b=1.8, p=0.011), and percentage of tumor cells with low oxygen concentration at simulation outset (hypoxic fraction) (b=1.0, p=0.034). In further analyses, we observed nominally significant relationships between IO benefit and hypoxic fraction measures taken across simulation timepoints. Significant relationships were salient in hypoxic fraction measures taken at early simulation timepoints, including weeks three (p=0.017), two (p=0.024), and five (p=0.038). Importantly, between IO benefit/hypoxic fraction relationships, we observed concordant positive directions of effect (i.e., higher hypoxic cancer fraction, higher IO benefit). Conclusion IO is likely to soon gain regulatory approval for early-stage TNBC, but biomarkers to predict benefit are lacking. PD-L1 expression has previously been correlated with hypoxic tumor environments and high density of tumor infiltrating lymphocytes. Even within a limited dataset, TS provided a biologically explainable marker to identify patients who may benefit from IO. Work is underway to further validate these findings in a larger dataset, and to validate hypoxic tumor fraction as a predictor of IO response. Citation Format: JR Pfeiffer, Joseph R. Peterson, Frederick Howard, Tyler M. Earnest, Tushar Pandey, Gong He, Rita Nanda. A multi-modal biomarker of immunotherapy response [abstract]. In: Proceedings of the 2021 San Antonio Breast Cancer Symposium; 2021 Dec 7-10; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2022;82(4 Suppl):Abstract nr P5-13-34.

Next generation immuno-oncology tumor profiling using a rapid, non-invasive, computational biophysics biomarker in early-stage breast cancer

A Novel Immuno-Oncology Algorithm Measuring Tumor Microenvironment To Predict Response To Immunotherapies

Abstract P5-13-34: A multi-modal biomarker of immunotherapy response

Association of a novel 27-gene immuno-oncology assay with efficacy of immune checkpoint inhibitors in advanced non-small cell lung cancer

Abstract PO2-03-10: Association of pathologic complete response with the 27-gene IO score and week 3 IOpath response following neoadjuvant pembrolizumab +/- intralymphatic cytokines in the neoIRX trial

A Novel Immunomodulatory 27-Gene Signature to Predict Response to Neoadjuvant Immunochemotherapy for Primary Triple-Negative Breast Cancer

Abstract P5-02-26: the 27-Gene IO Score is Associated with Pathologic Complete Response (pcr) in HR+/HER2- Breast Cancer Patients Treated with Pembrolizumab in the I-SPY2 Trial

The Immune-Related 27-Gene Signature DetermaIO Predicts Response to Neoadjuvant Atezolizumab plus Chemotherapy in Triple-Negative Breast Cancer

Multimodal machine learning model prediction of “individual” response to immunotherapy in 1L stage IV NSCLC.

Abstract 1158: Spatially resolved cell profiling unveils tumor metabolic states associated with immunotherapy response in NSCLC

The 27-gene IO score is associated with efficacy of PD-1/L1 inhibitors independent of FGFR expression in a real-world metastatic urothelial carcinoma cohort

Harnessing Liquid Biopsies to Guide Immune Checkpoint Inhibitor Therapy

Abstract 4146: Unlocking IO drug potential by high content imaging of immune cell co-cultures with cancer organoids from diverse cancer indications

A Novel Computational Framework for Predicting the Survival of Cancer Patients With PD-1/PD-L1 Checkpoint Blockade Therapy

Prediction of Immunotherapy Response by Integrating Immune Infiltration and Neoantigen Presentation Score in Late-Stage Melanoma.

Translation of the 27-Gene Immuno-Oncology Test (IO Score) to Predict Outcomes in Immune Checkpoint Inhibitor Treated Metastatic Urothelial Cancer Patients

Predicting patient outcomes after treatment with immune checkpoint blockade: A review of biomarkers derived from diverse data modalities

Multi-omic and spatial dissection of immunotherapy response groups in non–small cell lung cancer (NSCLC).

BIOM-31. TEMPOROSPATIAL PROTEIN PROFILING OF HUMAN GLIOBLASTOMAS REVEALS MOLECULAR MECHANISMS AND BIOMARKERS UNDERLYING RESPONSES TO IMMUNE CHECKPOINT INHIBITION

Prediction of immune checkpoint inhibition with immune oncology-related gene expression in gastrointestinal cancer using a machine learning classifier

Abstract PR-08: Spatial transcriptomics to profile the non-small cell lung cancer tumor microenvironment and identify novel predictive biomarkers for checkpoint blockade